This Phase II trial, sponsored by Vanderbilt-Ingram Cancer Center, investigates the efficacy of pemetrexed and platinum-based chemotherapy (carboplatin or cisplatin) with or without the EGFR TKI erlotinib in patients with stage IV non-small cell lung cancer (NSCLC) who have developed resistance to first-line EGFR TKIs. The trial's withdrawal due to lack of accrual raises concerns about market interest and patient recruitment strategies for similar studies. The competitive landscape includes other therapies targeting EGFR mutations and resistance mechanisms, indicating a need for differentiation in treatment approaches. Companies developing next-generation EGFR inhibitors or combination therapies may find this data relevant for positioning their assets in the market.